MT1-MMP: An enzyme with multidimensional regulation

Trends in Biochemical Sciences

Volumn 29, Issue 6, 2004, Pages 285-289

  Itoh, Yoshifumi ^a   Seiki, Motoharu ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; MATRIX METALLOPROTEINASE 14; MEMBRANE PROTEIN; PROTEINASE;

CELL FUNCTION; CELL SURFACE; DISEASE COURSE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LOCALIZATION; ENZYME REGULATION; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN GLYCOSYLATION; PROTEIN PROTEIN INTERACTION; REVIEW;

EID: 3242772983     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2004.04.001     Document Type: Short Survey

References (29)

1. r 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res. 50:1990;6184-6191
2. Overall C.M., Sodek J. Concanavalin A produces a matrix-degradative phenotype in human fibroblasts. Induction and endogenous activation of collagenase, 72-kDa gelatinase, and Pump-1 is accompanied by the suppression of the tissue inhibitor of matrix metalloproteinases. J. Biol. Chem. 265:1990;21141-21151
3. Sato H., et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 370:1994;61-65
4. Zucker S., et al. Membrane type-matrix metalloproteinases (MT-MMP). Curr. Top. Dev. Biol. 54:2003;1-74
5. Holmbeck K., et al. MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell. 99:1999;81-92
6. Seiki M. Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion. Cancer Lett. 194:2003;1-11
7. Zhou Z., et al. Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc. Natl. Acad. Sci. U. S. A. 97:2000;4052-4057
8. Hiraoka N., et al. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins. Cell. 95:1998;365-377
9. Hotary K.B., et al. Membrane type I matrix metalloproteinase usurps tumor growth control imposed by the three-dimensional extracellular matrix. Cell. 114:2003;33-45
10. Itoh Y., Nagase H. Matrix metalloproteinases in cancer. Essays Biochem. 38:2002;21-36
11. Rozanov D.V., et al. The low density lipoprotein receptor-related protein LRP is regulated by membrane type-1 matrix metalloproteinase (MT1-MMP) proteolysis in malignant cells. J. Biol. Chem. 279:2004;4260-4268
12. Koshikawa N., et al. Role of cell surface metalloprotease MT1-MMP in epithelial cell migration over laminin-5. J. Cell Biol. 148:2000;615-624
13. Itoh Y., et al. Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J. 20:2001;4782-4793
14. Lehti K., et al. Oligomerization through hemopexin and cytoplasmic domains regulates the activity and turnover of membrane-type 1 matrix metalloproteinase. J. Biol. Chem. 277:2002;8440-8448
15. Wu Y.I., et al. Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase. J. Biol. Chem. 279:2004;8278-8289
16. Oh J., et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell. 107:2001;789-800
17. Nakada M., et al. Testican 2 abrogates inhibition of membrane-type matrix metalloproteinases by other testican family proteins. Cancer Res. 63:2003;3364-3369
18. Lehti K., et al. Proteolytic processing of membrane-type-1 matrix metalloproteinase is associated with gelatinase A activation at the cell surface. Biochem. J. 334:1998;345-353
19. Stanton H., et al. The activation of ProMMP-2 (gelatinase A) by HT1080 fibrosarcoma cells is promoted by culture on a fibronectin substrate and is concomitant with an increase in processing of MT1-MMP (MMP-14) to a 45 kDa form. J. Cell Sci. 111:1998;2789-2798
20. Kinoshita T., et al. TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J. Biol. Chem. 273:1998;16098-16103
21. Mori H., et al. CD44 directs membrane-type 1 matrix metalloproteinase to lamellipodia by associating with its hemopexin-like domain. EMBO J. 21:2002;3949-3959
22. Uekita T., et al. Cytoplasmic tail-dependent internalization of membrane-type 1 matrix metalloproteinase is important for its invasion-promoting activity. J. Cell Biol. 155:2001;1345-1356
23. Jiang A., et al. Regulation of membrane-type matrix metalloproteinase 1 activity by dynamin-mediated endocytosis. Proc. Natl. Acad. Sci. U. S. A. 98:2001;13693-13698
24. Galvez B.G., et al. Caveolae are a novel pathway for membrane-type 1 matrix metalloproteinase traffic in human endothelial cells. Mol. Biol. Cell. 15:2004;678-687
25. Remacle A., et al. Membrane type I-matrix metalloproteinase (MT1-MMP) is internalised by two different pathways and is recycled to the cell surface. J. Cell Sci. 116:2003;3905-3916
26. Wang X., et al. Co-recycling of MT1-MMP and MT3-MMP through the trans-golgi network: identification of DKV582 as a recycling signal. J. Biol. Chem. 279:2004;9331-9336
27. Lu Z., et al. Downregulation of caveolin-1 function by EGF leads to the loss of E-cadherin, increased transcriptional activity of β-catenin, and enhanced tumor cell invasion. Cancer Cell. 4:2003;499-515
28. Overall C.M., Lopez-Otin C. Strategies for MMP inhibition in cancer: innovations for the post-trial era. Nat. Rev. Cancer. 2:2002;657-672
29. Zucker S., et al. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene. 19:2000;6642-6650